全文获取类型
收费全文 | 129194篇 |
免费 | 10168篇 |
国内免费 | 5204篇 |
专业分类
耳鼻咽喉 | 1151篇 |
儿科学 | 4008篇 |
妇产科学 | 1456篇 |
基础医学 | 24766篇 |
口腔科学 | 1372篇 |
临床医学 | 10750篇 |
内科学 | 29056篇 |
皮肤病学 | 1839篇 |
神经病学 | 5198篇 |
特种医学 | 2816篇 |
外国民族医学 | 14篇 |
外科学 | 6725篇 |
综合类 | 17444篇 |
现状与发展 | 29篇 |
预防医学 | 13852篇 |
眼科学 | 1015篇 |
药学 | 12195篇 |
32篇 | |
中国医学 | 4678篇 |
肿瘤学 | 6170篇 |
出版年
2023年 | 1460篇 |
2022年 | 2561篇 |
2021年 | 4828篇 |
2020年 | 4810篇 |
2019年 | 4554篇 |
2018年 | 4431篇 |
2017年 | 4067篇 |
2016年 | 4682篇 |
2015年 | 5329篇 |
2014年 | 8234篇 |
2013年 | 8597篇 |
2012年 | 7900篇 |
2011年 | 8711篇 |
2010年 | 7099篇 |
2009年 | 6763篇 |
2008年 | 6525篇 |
2007年 | 6626篇 |
2006年 | 5841篇 |
2005年 | 5128篇 |
2004年 | 4375篇 |
2003年 | 3817篇 |
2002年 | 3052篇 |
2001年 | 2763篇 |
2000年 | 2335篇 |
1999年 | 2058篇 |
1998年 | 1836篇 |
1997年 | 1673篇 |
1996年 | 1380篇 |
1995年 | 1413篇 |
1994年 | 1302篇 |
1993年 | 1020篇 |
1992年 | 893篇 |
1991年 | 739篇 |
1990年 | 673篇 |
1989年 | 583篇 |
1988年 | 533篇 |
1987年 | 409篇 |
1986年 | 369篇 |
1985年 | 875篇 |
1984年 | 740篇 |
1983年 | 550篇 |
1982年 | 537篇 |
1981年 | 453篇 |
1980年 | 371篇 |
1979年 | 343篇 |
1978年 | 276篇 |
1977年 | 201篇 |
1976年 | 225篇 |
1975年 | 169篇 |
1974年 | 148篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
目的分析昆明市2013-2017年丙型病毒性肝炎的流行特征和流行趋势,为科学制定防控策略提供依据。方法运用描述性流行病学方法,统计昆明市2013-2017年丙型病毒性肝炎的发病情况,分析其流行特征和趋势。结果昆明市2013-2017年丙型病毒性肝炎呈现先上升后下降的趋势,2015年达到发病高峰,其发病率高达32.80/10万,总体上2013-2017年丙型病毒性肝炎发病率呈现上升趋势,且肝炎和丙肝以官渡区、五华区和西山区为主要的高发地区;无明显的季节性特点,四季均有发病;易发生丙型病毒性肝炎的人群为35~50岁的农民和家务及待业人员。结论昆明市丙型病毒性肝炎发病状况并不乐观,应加强丙肝防控力度,重点关注高发地区和高发人群,通过有效举措控制丙型病毒性肝炎的发病率。 相似文献
72.
In the present study, we investigated the role of miR-122 in hepatocarcinoma progression and explored the
mechanism. In hepatocarcinoma tissues and cells, we used qRT-PCR to validate the miR-122 expression level.
Next, we used colony formation by crystal violet staining assay to compare cell proliferation ability, and we
used scratch test or Transwell assay to compare cell migration or invasion ability. We then conducted bioinformatics or luciferase reporter gene assay to prove the regulation effect of miR-122 on lamin B2 (LMNB2),
and the biological function of LMNB2 was analyzed. We used nude mouse tumorigenicity assay to test the
inhibition effect of miR-122 ASO therapy against hepatocarcinoma. miR-122 was reduced in hepatocarcinoma
tissues compared to the paracarcinoma tissues, which was relatively low or high in hepatocarcinoma cell line
SMMC7721 or Hep3B, and overexpressed miR-122 inhibited proliferation, migration, and invasion in hepatocarcinoma cells. Additionally, some reports showed that LMNB2 was regulated by miR-122, which inhibited
the expression of LMNB2. Moreover, LMNB2 functioned to promote cell proliferation, migration, and invasion. We could achieve the inhibition of hepatocarcinoma using miR-122 therapy through decreasing LMNB2
expression in vivo. Our data indicated that miR-122 could inhibit hepatocellular carcinoma cell progression by
targeting LMNB2 and as a therapeutic target for hepatocarcinoma treatment. 相似文献
73.
目的 初步探讨应用艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎(CHC)患者的疗效。方法 2017年3月~2018年3月仙桃市第一人民医院感染病科收治的CHC患者82例,被随机分为对照组41例和观察组41例,分别给予聚乙二醇干扰素-α联合利巴韦林治疗和艾尔巴韦/格拉瑞韦治疗,两组均连续治疗24周。采用RT- PCR法检测血清 HCV RNA,采用全基因序列测定法行病毒基因分型。比较两组早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)。结果 在治疗结束时,观察组血清丙氨酸氨基转移酶(ALT)水平为(47.9±19.7)U/L,显著低于对照组【(63.5±21.2)U/L,P<0.05】,天冬氨酸氨基转移酶(AST)水平为(55.5±22.3)U/L,显著低于对照组【(81.3±25.8)U/L,P<0.05】;观察组EVR、ETVR和SVR分别为48.8%、63.4%和70.7%,与对照组的41.5%、53.7%和65.8%比,无统计学差异(P>0.05);18例观察组非HCV Ⅰ型感染者EVR、ETVR和SVR分别为88.9%、94.4%和88.9%,显著高于同组23例HCV Ⅰ型感染者(分别为52.2%、60.9%和52.2%, P<0.05),而与对照组15例非HCV Ⅰ型感染者比,无统计学差异(分别为86.7%、93.3%和73.3%, P>0.05);观察组SVR12为87.8%(36/41),显著高于对照组的73.2%(30/41,P<0.05)。结论 应用直接抗病毒(DAA)药物艾尔巴韦/格拉瑞韦治疗CHC患者近期疗效达到,但远期疗效似优于标准治疗方案, 值得临床进一步验证。 相似文献
74.
75.
经典名方泽泻汤的HPLC指纹图谱及多指标含量测定研究 总被引:2,自引:0,他引:2
目的建立经典名方泽泻汤的HPLC指纹图谱,结合化学模式识别技术对其进行分析,并测定泽泻汤中3种成分23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的含量,为泽泻汤质量控制提供科学依据。方法采用Waters WAT054275C18色谱柱(250 mm×4.6 mm,5μm),以乙腈-水为流动相进行梯度洗脱,建立15批泽泻汤的HPLC指纹图谱,并采用"中药色谱指纹图谱相似度评价系统"、SPSS22.0及SIMCA14.1软件对15批泽泻汤的HPLC指纹图谱进行相似度评价及聚类分析(CA)、偏最小二乘判别分析(PLS-DA)等化学模式识别。同时测定23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的含量。结果建立了15批泽泻汤的HPLC指纹图谱,相似度均0.94,标定了18个共有峰,指认出3个色谱峰,分别为11号峰白术内酯Ⅲ、15号峰23-乙酰泽泻醇C、16号峰23-乙酰泽泻醇B,CA和PLS-DA将15批泽泻汤样品分为2类,同时15批泽泻汤中23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的质量分数分别为0.321~0.569、0.075~0.139、0.106~0.142 mg/g。结论 HPLC指纹图谱结合多成分同时测定的方法,快速、简便、重复性好,为泽泻汤及其制剂的质量评价提供参考。 相似文献
76.
77.
78.
Christos Loizou Göran Laurell Andreas Arvidsson David Lindquist Karin Nylander Katarina Olofsson 《Acta oto-laryngologica》2015,135(10):1058-1064
Conclusion: Recurrent respiratory papillomatosis (RRP) patients with high surgical treatment frequency (≥ 1/year, HF) were significantly younger and had a more widespread laryngeal disease compared to a low frequency treated group (< 1 treatment/year, LF). This study confirms the existence of a clinical RRP group, not primarily related to HPV sub-type, but more care-intensive and in need of more vigilant follow-up. Objectives: RRP is associated with high morbidity due to its influence on breathing and voice. The purpose of this study was to characterize RRP patients in northern Sweden and investigate possible predictor factors affecting therapeutic needs. Method: Patients from the regional referral area (northern Sweden) were categorized for age, disease duration, juvenile or adult onset, profile of disease development, number of surgical sessions in relation to disease duration, laryngeal deposition of papilloma, gender, and HPV sub-types, in order to identify patients with increased need for frequent surgical treatment. Results: The median age of the RRP patients (n = 48) was 44.5 years; 34 (71%) were males and 14 (29%) females, most were infected with HPV 6. Patients with high surgical treatment frequency/year were significantly younger and showed more widespread papillomatous vegetation in the larynx, compared to the low frequency treated group. 相似文献
79.
Hepatitis C is a major public health problem worldwide. This disease is caused by the hepatitis C virus, which is characterised by its genetic diversity. The infection is usually asymptomatic. However, between 60% and 80% of HCV-infected individuals will progress to chronic hepatitis, 20% to liver cirrhosis in the medium-to long-term and, each year, between 1% and 4% of these patients with cirrhosis will develop hepatocellular carcinoma (HCC). A Spanish consensus document has recently been drafted to diagnose hepatitis C in a single step, consisting of active investigation (antibodies and viremia) in a single sample, which according to the experts, would reduce the time to access treatment and avoid tracking losses. To definitively change the hepatitis C treatment paradigm, direct-acting antiviral drugs (DAAs) have been approved, whose development has been based on achieving cure rates close to 100% regardless of the genotype of the virus, ie, pangenotypes, with good tolerance and bioavailability. These drugs have constituted a real therapeutic revolution. Supplement information: This article is part of a supplement entitled «SEIMC External Quality Control Programme. Year 2016», which is sponsored by Roche, Vircell Microbiologists, Abbott Molecular and Francisco Soria Melguizo, S.A.© 2019 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosasy Microbiología Clínica. All rights reserved. 相似文献
80.